Since 2020, drug manufacturers' 340B contract pharmacy restrictions have greatly impacted health centers' ability to provide affordable medications to the patients that need them the most. NACHC conducted a survey to better understand the negative impact on patient outcomes due to the loss of 340B savings.

92% of respondents utilize 340B savings to increase access for low-income and/or rural patients by maintaining or expanding services in underserved communities.

90% of respondents report that their 340B program has led to improved medication adherence, improved clinical outcomes, and improved access to care.

Health center patients with diabetes, heart disease, and behavioral health needs rely on drugs purchased through the 340B program more than other patient population. Without 340B, these patients would face much more severe health outcomes.

Additionally, 32% of respondents believe that over half of their patients would lose access to needed medication without 340B program discounts.

Data comes from 302 individual health center respondents to NACHC's 340B survey, fielded from April 11 to May 13. For more information see accompanying report or contact Gracy Trinoskey-Rice at gtrinoskeyrice@nachc.org.